Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
Mené sur 40 patients atteints d'un cancer du poumon non épidermoïde non à petites cellules de stade avancé et présentant des métastatases cérébrales (durée médiane de suivi : 31 mois), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression en semaine 12, et la toxicité d'un traitement combinant atézolizumab et chimiothérapie (carboplatine et pémétrexed)
Brain metastases are an increasingly frequent complication in patients with cancer, occurring in over 70,000 patients in the United States annually.1 Non–small-cell lung cancer (NSCLC) is the most common cause of brain metastases, and up to 40% of patients with advanced NSCLC will develop intracranial involvement during the course of their disease.2 Despite improvements in imaging modalities to facilitate screening and early detection, as well as advances in local and systemic therapies, brain metastases continue to be associated with poor prognoses
Journal of Clinical Oncology , éditorial en libre accès, 2022